Bibliography
Export 48 results:
Filters: Keyword is Research Support, Non-U.S. Gov't [Clear All Filters]
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(5):511-7.
Aspergillus fumigatus. Mol Diagn Ther. 2006;10(2):125-34.
Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. Transplantation. 2005;80(1):26-33.
A generalized seizure in a renal allograft recipient. Nephrol Dial Transplant. 2005;20(4):834-6.
Post-transplant lymphoproliferative disorder. Clin Chest Med. 2005;26(4):631-45, - vii.
Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol. 2005;53(5):783-90.
Organ donors with malignant gliomas: an update. Am J Transplant. 2004;4(1):15-21.
Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone Marrow Transplant. 2004;34(8):657-65.
Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76(9):1289-93.
Donor origin of de novo hepatocellular carcinoma in hepatic allografts. Transplantation. 2003;76(5):871-3.
If the donor had an early-stage genitourinary carcinoma and the liver has already been implanted, should we perform the transplantectomy? Liver Transpl. 2003;9(12):1281-5.
Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol. 2003;162(6):1823-9.
Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med. 2003;9(5):554-61.
T-cell large granular lymphocyte leukemia of donor origin after allogeneic bone marrow transplantation. Am J Clin Pathol. 2003;120(4):626-30.
Activation of Kupffer cells inhibits tumor growth in a murine model system. Int J Cancer. 2002;99(5):713-20.
Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant. 2002;29(5):449-52.
Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma. Br J Haematol. 2002;119(3):777-80.
Transplant tumor registry: donors with central nervous system tumors1. Transplantation. 2002;73(4):579-82.
Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR-ABL fusion transcripts detected using a new real-time polymerase chain reaction method. Br J Haematol. 2001;113(4):1072-5.
Induction of Fas and Fas ligand expression on malignant glioma cells by Kupffer cells, a potential pathway of antiliver metastases. J Surg Res. 2001;101(1):44-51.
UNOS Transplant Tumor Registry: donors with a history of cancer. Transplant Proc. 2001;33(40575):1844-5.
Donor origin of neuroendocrine carcinoma in 2 transplant patients determined by molecular cytogenetics. Hum Pathol. 2000;31(11):1425-9.
First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation. 2000;70(12):1747-51.
Need for an accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem cell transplantation. Haematologica. 2000;85(11):1153-7.
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208-16.